Transgenic T cells for Lymphoblastic Leukemia

Lead Inventor: Adolfo Ferrando, M.D., Ph.D. Lymphoblastic leukemia models using T cell strain: T-cell lymphoblastic leukemia (T-ALL) is a rare cancer of the immune system's own T-cells. A treatment for this cancer is needed. This technology provides CUTLL1 cells, which will be useful as an experimental model for T-ALL and for testing of therapeutic strategies. Cells for lymphoblastic leukemia drug development : Activating mutations in NOTCH1 are present in over 50% of human T-ALLs. This human T-cell lymphoma line CUTLL1, expresses high levels of activated NOTCH1 and is extremely sensitive to γ-secretase inhibitors treatment. CUTLL1 cells harbor a t(7;9)(q34;q34) chromosomal translocation which induces the expression of a TCRB-NOTCH1 fusion transcript encoding a membrane-bound truncated form of the NOTCH1 receptor. Applications: • Testing therapeutic strategies to treat T-ALL Advantages: • This technology provides a model system for the study of T-ALL Patent Status: Copyright Licensing Status: Copyright / Material available for Express Licensing CUTLL1 cells Publications: CUTLL1, a novel human T-cell lymphoma line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Palomero, T et al. (2006) Leukemia. 20:1279-87.